Pharmaceutical

Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases

The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.

Aug 27, 2024 - 04:00
Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases
The European Commission (EC) has approved Celltrion's SteQeyma, a biosimilar to Stelara, for treating chronic inflammatory conditions.
Read the original article

Tags:

Previous Article

MSD snags European approval for pulmonary arterial hypertension therapy

Next Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Here are the dozens of weight loss drugs in development to catch a booming market

STAT+: Here are the dozens of weight loss drugs in deve...

Sep 12, 2023

STAT+: Scientists take a (small) step toward universal antivenom

STAT+: Scientists take a (small) step toward universal ...

Feb 21, 2024

EMA endorses Calliditas’ Alport syndrome drug for orphan designation

EMA endorses Calliditas’ Alport syndrome drug for orpha...

Oct 5, 2023